Download PDF
Dialyse aktuell 2016; 20(08): 385-388
DOI: 10.1055/s-0042-116372
Transplantation
© Georg Thieme Verlag Stuttgart · New York

Calcineurininhibitoren

Wie ist ihre Rolle in der Immunsuppression nach Nierentransplantation?Calcineurin inhibitors – What is their role in immunosuppression after kidney transplantation?
Alexander Reshetnik
1   Med. Klinik mit SP Nephrologie, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin (Klinikdirektor: Prof. Dr. Walter Zidek)
› Author Affiliations
Further Information

Publication History

Publication Date:
10 October 2016 (online)

Also available at
    Permissions and Reprints

Die Entdeckung und flächenhafte Verwendung der Calcineurininhibitoren (CNI) hat die Prognose der Patienten nach solider Organtransplantation entscheidend verbessert. Mit Ciclosporin A und Tacrolimus stehen uns 2 Medikamente aus der Gruppe der CNI zur Verfügung, die zwar insgesamt gut verträglich sind, jedoch individuelle Nebenwirkungsprofile aufweisen. Die Kenntnis dieser Nebenwirkungen ist im Umgang mit diesen Medikamenten unabdingbar. Insbesondere die CNI-assoziierte Nephrotoxizität kann entscheidend für die Langzeitprognose des Transplantates sein, sodass inzwischen zahlreiche Evidenzen zur Niedrigdosis-CNI oder zu CNI-freien Regimes generiert wurden. Zu beachten ist jedoch, dass durch die Reduktion der CNI-Dosis oder das Absetzen von CNI das Risiko für Abstoßungsreaktionen (insbesondere chronische humorale Abstoßung) steigen kann, was das Transplantatüberleben limitiert.

The discovery and extended use of calcineurin inhibitors (CNI) improved the survival of the kidney allograft after transplantation significantly. Ciclosporin and tacrolimus – available CNI agents – appear to be well tolerated. However, both agents show different side effects profiles. The knowledge of these side effects is mandatory for the choice of the particular agent. Especially CNI-associated nephrotoxicity is an important issue and can impair the long-term allograft survival. Thus, several low-dose CNI or CNI-spare regimes have been developed. Usage of such regimes may improve long-term kidney function. However, increased risk of rejection, in particular chronic humoral rejection, should be noted.

Key words

calcineurin inhibitors - immunosuppression - kidney transplantation - nephrotoxicity - allograft survival
 

  • Literatur

  • 1 Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 2002; 114: 433-437
    Google Scholar
  • 2 Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468-475
    CrossrefGoogle Scholar
  • 3 Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without …. J Immunol 2013; 191: 5785-5791
    CrossrefGoogle Scholar
  • 4 Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc 2004; 36: 2096-2097
    CrossrefGoogle Scholar
  • 5 Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83: 1525-1535
    CrossrefGoogle Scholar
  • 6 Navaneethan SD, Sankarasubbaiyan S, Gross MD et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006; 38: 1320-1322
    CrossrefGoogle Scholar
  • 7 Lee CT, Huynh VM, Lai LW, Lien YH. Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice. Kidney Int 2002; 62: 2055-2061
    CrossrefGoogle Scholar
  • 8 Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767-774
    CrossrefGoogle Scholar
  • 9 Mihatsch MJ, Kyo M, Morozumi K et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363
    Google Scholar
  • 10 Lin CC, King KL, Chao YW et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580-585
    Google Scholar
  • 11 Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf 2015; 14: 1531-1546
    CrossrefGoogle Scholar
  • 12 Kobashigawa JA, Patel J, Furukawa H et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25: 434-439
    CrossrefGoogle Scholar
  • 13 Lucey MR, Abdelmalek MF, Gagliardi R et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5: 1111-1119
    CrossrefGoogle Scholar
  • 14 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
    CrossrefGoogle Scholar
  • 15 Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885
    CrossrefPubMedGoogle Scholar
  • 16 de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416-435
    CrossrefGoogle Scholar
  • 17 Langer RM, Hené R, Vitko S et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant Int 2012; 25: 592-602
    CrossrefGoogle Scholar